Life Sciences

  • August 24, 2026

    Judge Orders $245M In Guardant Damages In DNA Patent Suit

    A judge has boosted what Guardant Health Inc. owes in a case in which it was found to have infringed two TwinStrand Biosciences Inc. patents covering methods of lowering the error rate in DNA sequencing, bringing the total to $245 million.

  • August 24, 2026

    Rising Star: Paul Weiss' Benjamin Goodchild

    Benjamin Goodchild of Paul Weiss Rifkind Wharton & Garrison LLP developed an innovative deal structure while guiding obesity drug developer Metsera Inc. through a tumultuous bidding war that resulted in its acquisition by Pfizer Inc., earning him a spot among the life sciences law practitioners under age 40 honored by Law360 as Rising Stars.

  • August 24, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week saw a wave of lawsuits involving corporate oversight, take-private deals, financing transactions, bankruptcy fallout, stockholder voting rights and disputes over control.

  • August 21, 2026

    Cytek Hit With $56M Verdict For Infringing Cell-Sorting Patent

    A Delaware federal jury Friday awarded roughly $36 million in damages to biomedical testing manufacturer Beckman Coulter after finding that Cytek Biosciences infringed one of its patents covering a technology that quickly analyzes single cells.

  • August 21, 2026

    Trump Seeks Justices' Review Of DEI Grant Termination Case

    The Trump administration is urging the U.S. Supreme Court to review a Ninth Circuit decision requiring the federal government to reinstate research grants that were terminated due to presidential orders against diversity, equity and inclusion initiatives.

  • August 21, 2026

    Pharma Co. Loses Challenge To $3M Acne Drug Arb. Award

    A New York federal court confirmed an arbitrator's finding that Sun Pharmaceuticals breached an agreement with the owner of an acne drug by seeking regulatory approval to market a version of the drug in Canada, rejecting arguments that the arbitrator wrongly relied on extrinsic evidence.

  • August 21, 2026

    Hogan Lovells Helps Advance Gene Therapy For Rare Disease

    Hogan Lovells Cadwalader partner Blake Wilson found himself scrolling through LinkedIn one day, when a post caught his eye that would spark a multiyear pro bono effort and lead to a breakthrough treatment for a rare and fatal disorder affecting children.

  • August 21, 2026

    Astrid Investor Asks Chancery Court To Order Annual Meeting

    A director and major stockholder of Astrid Pharma Corp. has asked the Delaware Chancery Court to force the company to hold its 2026 annual meeting, saying it has gone years without giving stockholders the chance to elect directors.

  • August 21, 2026

    Bio-Techne Gives FTC More Time On $11.3B Merck Deal

    Life science tool company Bio-Techne has withdrawn and refiled its intent to merge with pharmaceutical giant Merck in an $11.3 billion deal in order to give the Federal Trade Commission more time to scrutinize the deal for competition concerns.

  • August 21, 2026

    Cook Medical Hit With Data Breach Class Suit

    A medical equipment manufacturer failed to protect employees' sensitive data from a cyberattack, potentially exposing their personal information to the dark web, a former employee alleged in a new proposed class action in Indiana federal court.

  • August 20, 2026

    Abbott Inks $670M Deal To End Some Preterm Formula Claims

    Abbott Laboratories announced Thursday that it has agreed to pay about $670 million to partially resolve ongoing litigation alleging its specialty baby formula caused premature babies to suffer a disabling intestinal condition.

  • August 20, 2026

    FTC Slams Amgen's Antitrust Shield Argument At 4th Circ.

    The Federal Trade Commission has urged the Fourth Circuit to reject Amgen's "sweeping" assertion that commercial agreements for acquiring the rights to patent applications are shielded from antitrust scrutiny, saying the company's position in an appeal related to blockbuster autoimmune drug Enbrel is a threat to longstanding understandings of antitrust law.

  • August 20, 2026

    J&J Talc Unit Loses Libel Suit Over Flawed Cancer Study

    A Virginia federal judge handed three doctors a win Wednesday in a Johnson & Johnson subsidiary's libel lawsuit over a 2020 study linking cosmetic talc exposure to mesothelioma, finding the subsidiary's evidence didn't show the trio knowingly or recklessly published falsehoods and instead merely revealed the doctors' "fear of litigation."

  • August 20, 2026

    SEC Won't Lift Trading Suspension On Chinese Biotech Firm

    The U.S. Securities and Exchange Commission has upheld Nasdaq's decision to delist the stock of Shineco Inc. after the Chinese biotech firm repeatedly violated the exchange's listing requirements, rejecting the company's arguments that a Nasdaq hearing panel reached its decision too quickly and did not properly consider plans for new operations at Shineco.

  • August 20, 2026

    USPTO Tells Fed. Circ. 'Settled Expectations' Is Constitutional

    The U.S. Patent and Trademark Office has urged the Federal Circuit to reject Google's constitutional challenge to the office's "settled expectations" policy of taking the age of patents into account when deciding whether to review them, saying the rule is "eminently rational."

  • August 20, 2026

    Canadian Bioscience Cos. Settle 'Fake' Fuel Trading Suit

    A Colorado state judge agreed to issue a stay and administratively close a case brought by two Canadian bioscience companies alleging that a Denver resident defrauded them out of nearly $1 million through "fake" fuel trading deals, amid an undisclosed agreement reached between the parties.

  • August 20, 2026

    Latest Squires Order Grants 2 Patent Petitions, Denies None

    U.S. Patent and Trademark Office Director John Squires has issued a brief bulk order instituting a pair of America Invents Act petitions, including a Google challenge to a Valtrus Innovations patent, and saying he would assess the merits of four other patent challenges.

  • August 20, 2026

    Amgen Reaches Deal To End Ex-Worker's Tobacco Fee Fight

    Biotech giant Amgen Inc. struck a deal to end a proposed class action alleging a $150-a-month fee on the health plans of employees who used tobacco violated federal benefits law, according to a filing in California federal court Thursday.

  • August 20, 2026

    Sangamo Ch. 11 Auction Nets $238M In Offers

    A Delaware bankruptcy judge Thursday agreed to approve a trio of sales that will bring in $52 million in cash for Sangamo Therapeutics, after attorneys representing the life sciences group told the court a competitive Chapter 11 auction ended with four winning bids worth over $238 million.

  • August 20, 2026

    Eagle Pharma $9.5M Investor Deal Gets Final OK

    A $9.5 million settlement resolving claims that Eagle Pharmaceuticals Inc. and its former executives carried out a fraudulent "channel stuffing" scheme to inflate the revenue of one of the company's brand-name medications has received the final stamp of approval from a New Jersey federal magistrate judge.

  • August 20, 2026

    Dentons Hires Longtime K&L Gates Healthcare Lawyer

    Dentons has hired a K&L Gates LLP healthcare partner and office managing partner who spent more than 17 years at that firm advising pharmaceutical, biotechnology, medical device and other life sciences clients on regulatory, compliance and transactional matters.

  • August 19, 2026

    NYC's DNA Policies Led To Fabricated Evidence, Suit Says

    A man who was wrongfully convicted of raping a woman claims he was framed by the New York City medical examiner's office, alleging in a federal lawsuit Wednesday that the agency's unconstitutional protocols led forensic analysts to generate fabricated DNA evidence that misled the prosecution and jury.

  • August 19, 2026

    5th Circ. Tells FDA To 'Rethink' Rule Behind E-Cig Rejection

    The Fifth Circuit on Wednesday agreed with vaping companies that the U.S. Food and Drug Administration overstepped its authority when it repeatedly blocked approval of flavored e-cigarettes without a notice-and-comment period, holding that the repeated denials constitute a rule that the agency must "rethink" or readopt properly.

  • August 19, 2026

    Abbott Deal Ends Appeal After $495M Baby Formula Trial Loss

    Abbott Laboratories Inc. has struck a deal with a family that won a $495 million judgment against the U.S. pharmaceutical company in a bellwether trial over claims that its baby formula caused a premature baby to suffer a disabling condition, after a midlevel appellate court upheld the win, according to court filings.

  • August 19, 2026

    1st Circ. Says Apellis Disclosures Weren't 'Half-Truths'

    A First Circuit panel on Wednesday affirmed the dismissal of a securities fraud lawsuit accusing Apellis Pharmaceuticals and some of its top executives of misleading investors about the safety testing of the company's eye drug Syfovre, finding no actionable claim the company told "half-truths" about potential side effects of inflammation that can lead to blindness. 

Expert Analysis

  • Virginia's Cannabis Retail Veto Leaves Industry In Legal Limbo

    Author Photo

    Virginia Gov. Abigail Spanberger's recent veto of legislation that would have established a regulated retail cannabis framework halts momentum built by the General Assembly, but it also sends important signals about what a future regulatory framework must address to survive, says Charles Slemp at Cozen.

  • Checking For AI Errors Is Now A Two-Way Street

    Author Photo

    A handful of recent federal and state cases demonstrate the importance of checking for errors generated by artificial intelligence not only in your own court submissions, but also your opponent's, as well as when catching opposing counsel's AI mistakes could result in an award for attorney fees, says Tamara Barago at Hollingsworth.

  • Series

    The Biz Court Digest: Shoring Up Corporate Law In Maryland

    Author Photo

    Launched more than 20 years ago to improve complex corporate adjudication, Maryland's Business and Technology Case Management Program has been a solid success in some areas, but there always is room for improvement, says Bill Krulak at Miles & Stockbridge.

  • State Enviro Agencies Give Cosmetics Regulation A Makeover

    Author Photo

    As state oversight of cosmetics rapidly expands, the new statutes and regulations governing these products are being implemented by environmental agencies rather than consumer product regulators, requiring manufacturers, distributors and retailers to reevaluate their supply chains and procedures, say attorneys at Baker Botts.

  • FDA's Chemical Review Process Heats Up Food Industry Risk

    Author Photo

    The U.S. Food and Drug Administration's newly announced process for postmarket assessment of food additives signals a significant shift away from historically limited oversight, introducing both strategic opportunities and material risks for food manufacturers, ingredient suppliers and others in the food supply chain, say attorneys at Morgan Lewis.

  • Series

    Competing At Poker Makes Me A Better Lawyer

    Author Photo

    Playing poker in male-dominated rooms taught me to treat skepticism as background noise when my opponents seem to underestimate me, to apply pressure when it matters and to adapt without losing strategic discipline — skills that are all indispensable in restructuring and insolvency matters, says Alexis Gambale at Pashman Stein.

  • Why IPR Slowdown Has Not Led To More Patent Litigation

    Author Photo

    Despite sustained strength in patent application filings and a decline in inter partes review and post-grant review, 2026 has not seen the anticipated surge in patent litigation in district courts and at the U.S. International Trade Commission, potentially due to four reasons, say attorneys at Sterne Kessler.

  • 5 Things Associates Must Ask About Their Firm's Merger Plan

    Author Photo

    The associates who navigate law firm mergers best ask the right questions early, such as inquiring about partners' plans, to assess how the merger could affect their workflow and career path, says Jackie Bokser-LeFebvre at Major Lindsey.

  • Brain Computer Interfaces Boot Up Multipronged Legal Issues

    Author Photo

    As neurotechnology companies begin to conduct human clinical trials for brain computer interfaces, attorneys should prepare for legal ramifications across a broad range of practice areas, including intellectual property, privacy and product liability, say attorneys at ArentFox Schiff.

  • Turning To The Courts When PBM Reform Falls Short

    Author Photo

    The effectiveness of state laws intended to regulate pharmacy benefit managers remains uncertain, but litigation — utilizing tried-and-true theories like breach of contract and fair dealing — offers another mechanism through which stakeholders may seek relief from PBMs, say attorneys at Reed Smith.

  • 2 'Rocket Dockets' And The Rules That Propel Them

    Author Photo

    The fastest civil trial courts in the country are currently in the Eastern District of Virginia and the Southern District of Florida, and their chief judges provide insights into the court rules that keep them ahead, says Robert Tata at Hunton.

  • Calif. Ruling Lowers Bar For Health Data Breach Claims

    Author Photo

    The California Supreme Court's ruling in J.M. v. Illuminate Education offers protection for non-healthcare companies that maintain health-related data but also adopts a new and more plaintiff-favorable standard for breach of confidentiality that companies maintaining any health-related data should address, say attorneys at Cooley.

  • Teva Ruling Offers Patentees New Support For Genus Claims

    Author Photo

    The Federal Circuit's recent decision in Teva v. Eli Lilly, finding that the Teva patents at issue are not invalid, offers an interesting counterexample against the recent trend of courts invalidating patents claiming a broad, functionally defined class of compounds, say attorneys at Cooley.

  • Your Next Litigation Hold Should Cover AI Chat Logs

    Author Photo

    The Delaware Chancery Court’s recent decision in Fortis Advisors v. Krafton to treat a CEO’s artificial intelligence chats as substantive evidence is being read as a discovery warning to litigators, but there is a second duty-to-preserve lesson that is especially pertinent to in-house counsel, say attorneys at Faegre Drinker.

  • Opinion

    High Court's Abortion Pill Stay Reinforces Appellate Principles

    Author Photo

    The U.S. Supreme Court's recent order in Danco Laboratories v. Louisiana, staying a Fifth Circuit ruling that reinstated an in-person requirement for dispensing the abortion medicine mifepristone, should be seen not as a definitive ruling on reproductive rights, but as an affirmation of a more disciplined jurisdictional reality, says Daniel Nardo at Nardo & Associates.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.